vs
Side-by-side financial comparison of EVERSPIN TECHNOLOGIES INC. (MRAM) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
EVERSPIN TECHNOLOGIES INC. is the larger business by last-quarter revenue ($14.9M vs $13.7M, roughly 1.1× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -2.0%, a 77.7% gap on every dollar of revenue.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
MRAM vs XLO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.9M | $13.7M |
| Net Profit | $-296.0K | $10.4M |
| Gross Margin | 52.7% | — |
| Operating Margin | 29.0% | -86.5% |
| Net Margin | -2.0% | 75.7% |
| Revenue YoY | 13.2% | — |
| Net Profit YoY | — | 179.1% |
| EPS (diluted) | $-0.01 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.9M | — | ||
| Q4 25 | $14.8M | $13.7M | ||
| Q3 25 | $14.1M | $19.1M | ||
| Q2 25 | $13.2M | $8.1M | ||
| Q1 25 | $13.1M | $2.9M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $12.1M | — | ||
| Q2 24 | $10.6M | — |
| Q1 26 | $-296.0K | — | ||
| Q4 25 | $1.2M | $10.4M | ||
| Q3 25 | $54.0K | $-16.3M | ||
| Q2 25 | $-670.0K | $-15.8M | ||
| Q1 25 | $-1.2M | $-13.3M | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $-2.5M | — |
| Q1 26 | 52.7% | — | ||
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.3% | — | ||
| Q2 25 | 51.3% | — | ||
| Q1 25 | 51.4% | — | ||
| Q4 24 | 51.3% | — | ||
| Q3 24 | 49.2% | — | ||
| Q2 24 | 49.0% | — |
| Q1 26 | 29.0% | — | ||
| Q4 25 | -7.2% | -86.5% | ||
| Q3 25 | -11.0% | -10.1% | ||
| Q2 25 | -14.9% | -177.7% | ||
| Q1 25 | -14.7% | -472.7% | ||
| Q4 24 | -11.8% | — | ||
| Q3 24 | -17.5% | — | ||
| Q2 24 | -26.5% | — |
| Q1 26 | -2.0% | — | ||
| Q4 25 | 8.1% | 75.7% | ||
| Q3 25 | 0.4% | -85.4% | ||
| Q2 25 | -5.1% | -196.0% | ||
| Q1 25 | -8.9% | -452.7% | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 18.8% | — | ||
| Q2 24 | -23.5% | — |
| Q1 26 | $-0.01 | — | ||
| Q4 25 | $0.05 | $-3.74 | ||
| Q3 25 | $0.00 | $-0.11 | ||
| Q2 25 | $-0.03 | $-0.16 | ||
| Q1 25 | $-0.05 | $-0.18 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.10 | — | ||
| Q2 24 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.5M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $70.2M | $35.3M |
| Total Assets | $83.2M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.5M | — | ||
| Q4 25 | $44.5M | $137.5M | ||
| Q3 25 | $45.3M | $103.8M | ||
| Q2 25 | $45.0M | $121.6M | ||
| Q1 25 | $42.2M | $89.1M | ||
| Q4 24 | $42.1M | — | ||
| Q3 24 | $39.6M | — | ||
| Q2 24 | $36.8M | — |
| Q1 26 | $70.2M | — | ||
| Q4 25 | $68.9M | $35.3M | ||
| Q3 25 | $65.8M | $-8.1M | ||
| Q2 25 | $64.1M | $7.1M | ||
| Q1 25 | $63.0M | $10.7M | ||
| Q4 24 | $62.6M | — | ||
| Q3 24 | $59.3M | — | ||
| Q2 24 | $55.4M | — |
| Q1 26 | $83.2M | — | ||
| Q4 25 | $84.6M | $154.7M | ||
| Q3 25 | $80.3M | $133.7M | ||
| Q2 25 | $78.9M | $133.8M | ||
| Q1 25 | $80.2M | $103.7M | ||
| Q4 24 | $77.8M | — | ||
| Q3 24 | $72.6M | — | ||
| Q2 24 | $64.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $570.0K | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $570.0K | — | ||
| Q4 25 | $2.6M | $-2.0M | ||
| Q3 25 | $881.0K | $-17.5M | ||
| Q2 25 | $5.0M | $-14.5M | ||
| Q1 25 | $1.4M | $29.0M | ||
| Q4 24 | $3.8M | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $1.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-975.0K | $-2.1M | ||
| Q3 25 | $543.0K | — | ||
| Q2 25 | $3.0M | $-14.9M | ||
| Q1 25 | $527.0K | $29.0M | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $1.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | -6.6% | -15.3% | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 22.9% | -184.0% | ||
| Q1 25 | 4.0% | 988.3% | ||
| Q4 24 | 15.8% | — | ||
| Q3 24 | 22.9% | — | ||
| Q2 24 | 15.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 24.3% | 0.7% | ||
| Q3 25 | 2.4% | 0.0% | ||
| Q2 25 | 15.1% | 5.0% | ||
| Q1 25 | 6.9% | 0.8% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.19× | -0.19× | ||
| Q3 25 | 16.31× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.16× | — | ||
| Q3 24 | 1.25× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
XLO
Segment breakdown not available.
